GMR
The Original

ENGINEERING CRISPR BASE EDITING TECHNOLOGIES FOR TREATMENT OF INHERITED BLOOD DISORDERS

Suresh Arumugam[1], Dr. Eswari V[2], Dr. Mohanraj P[3], Dr. Lokeshwari V[4], Dr. Nishanth S[5]

[1] Scientist, Central Research Laboratory, Meenakshi Medical College Hospital & Research Institute, Meenakshi Academy of Higher Education and Research, Chennai, Tamil Nadu, India.
[2] Professor & Head of Department, Department of Pathology, Meenakshi Medical College Hospital & Research Institute, Meenakshi Academy of Higher Education and Research, Enathur, Kanchipuram, Tamil Nadu – 631552, India.
[3] Professor, Department of General Medicine, Meenakshi Medical College Hospital & Research Institute, Meenakshi Academy of Higher Education and Research, Enathur, Kanchipuram, Tamil Nadu – 631552, India.
[4] Associate Professor, Department of Pathology, Meenakshi Medical College Hospital & Research Institute, Meenakshi Academy of Higher Education and Research, Enathur, Kanchipuram, Tamil Nadu – 631552, India.
[5] Assistant Professor, Department of General Medicine, Meenakshi Medical College Hospital & Research Institute, Meenakshi Academy of Higher Education and Research, Enathur, Kanchipuram, Tamil Nadu – 631552, India.

ABSTRACT

Background: Inherited blood disorders such as sickle cell disease (SCD) and β-thalassemia are caused by single-gene mutations that disrupt normal hemoglobin synthesis and red blood cell function. Standard therapies such as bone marrow transplantation and lifelong transfusions are still limited by donor availability, immune complications and treatment-related toxicity. Recent advances in CRISPR base editing technologies enable precise genome modification without inducing double-stranded DNA breaks, which in turn reduces genomic instability and off-target effects.

Objective: To evaluate engineered CRISPR base editing systems for correction of pathogenic mutations associated with inherited blood disorders.

Methods: It applied adenine base editors (ABEs) and cytosine base editors (CBEs) to correct β-globin gene mutations in hematopoietic stem cells. We evaluated editing efficiency, hemoglobin restoration, and genomic safety by next-generation sequencing, flow cytometry, and functional erythroid differentiation assays.

Findings: Base editing resulted in ~78–85% mutation correction efficiency and <2% detectable off-target activity. The treated cells exhibited 65% increase of functional haemoglobin expression and a significant improvement of erythroid maturation compared to untreated controls.

Conclusions: Engineered CRISPR base editing is a promising therapeutic approach for inherited blood disorders that could achieve precise, efficient and potentially curative genome correction with improved safety profiles.

KEYWORDS: CRISPR base editing, sickle cell disease, β-thalassemia, hematopoietic stem cells, genome engineering, adenine base editor, cytosine base editor, inherited blood disorders.

1 INTRODUCTION

Inherited blood disorders like sickle cell disease (SCD) and β-thalassemia are among the most common monogenic diseases globally, mainly due to mutations in the β-globin (HBB) gene, which lead to impaired hemoglobin synthesis and red blood cell function [1]. These conditions can result in severe anemia, chronic pain, organ damage, and a shortened lifespan. Treatment options such as blood transfusions, hydroxyurea therapy, and hematopoietic stem cell transplantation are used to achieve symptomatic relief, but are limited by challenges such as availability of donors, immune rejection, iron overload, and high treatment costs [2]. The development of precise genome engineering technologies capable of permanent correction of pathogenic mutations is thus of increasing interest.

The emergence of CRISPR-Cas genome editing systems has transformed the field of molecular medicine with the specific editing of disease-associated genes [3]. Standard techniques for genome editing with CRISPR-Cas9 depend on double-stranded DNA breaks (DSBs) and subsequent homology-directed repair (HDR) or non-homologous end joining (NHEJ) that may lead to unintended insertions/deletions and genomic instability [4]. To overcome these limitations, CRISPR base editing technologies have been developed that enable direct conversion of nucleotides without generation of DSBs . Base editors fuse catalytically impaired Cas proteins to nucleobase deaminases for highly specific adenine-to-guanine or cytosine-to-thymine conversion [5]. Recent breakthroughs in adenine base editors (ABEs) and cytosine base editors (CBEs) have demonstrated significant potential for rescuing pathogenic mutations related to inherited blood disorders [6]. In sickle cell disease, CRISPR base editing has been successfully used to modify HBB mutation or to reactivate fetal hemoglobin (HbF) expression by targeting BCL11A enhancer [7]. Likewise, mutations related to β-thalassemia have been repaired in hematopoietic stem and progenitor cells with high editing efficiency and low off-target

activity [8]. These strategies provide significant therapeutic advantages, such as higher editing accuracy, reduced cytotoxicity, and enhanced genomic safety

Despite promising progress, several technical and clinical challenges remain unsolved. Efficient delivery of base editors into hematopoietic stem cells remains challenging because of the variability in transfection efficiency and the potential for immunogenicity [9]. Off-target nucleotide conversions, bystander editing, and long-term genomic stability are also still raising safety concerns for clinical applications [10]. Moreover, the large-scale clinical validation and long-term therapeutic monitoring are still limited, restricting the broad translational implementation [11].

Thus, the development of next-generation CRISPR base editing technologies may provide an unprecedented opportunity for treating inherited blood diseases via accurate and permanent genome editing.

1.1 Research Gap

However, the current studies are constrained by limited long-term safety evaluation, inefficient delivery systems in hematopoietic stem cells and poor understanding of off-target genomic effects, despite the promising therapeutic effects of CRISPR base editing technologies. Also, standardized clinical protocols for large scale therapeutic application are still under-developed.

1.2 Objectives

1. To evaluate the efficiency and precision of CRISPR base editing technologies in correcting pathogenic mutations associated with inherited blood disorders.
2. To analyze the therapeutic potential, safety profile, and clinical applicability of engineered base editing systems in hematopoietic stem cells.

2 Background work

2.1 CRISPR Base Editing Technologies

New developments in CRISPR base editing technologies have made genome engineering in inherited blood disorders much more precise. The adenine base editors (ABEs) and cytosine base editors (CBEs) permit direct nucleotide conversion with less genomic instability, instead of the classical CRISPR-Cas9 that causes double-stranded DNA cuts [12]. Base editing systems have been shown to effectively correct β-globin mutations in hematopoietic stem cells with editing efficiencies of >80%, demonstrating their therapeutic potential [13].

2.2 Applications in Inherited Blood Disorders

CRISPR base editing has shown promising results for the treatment of sickle cell disease (SCD) and β-thalassemia. Recent studies have demonstrated the re-expression of fetal hemoglobin (HbF) expression by targeted editing of the BCL11A enhancer region, which resulted in significant alleviation of sickling phenotypes [14]. In β-thalassemia models, engineered base editors rescued normal erythroid differentiation and hemoglobin production with minimal cytotoxicity [15]. These findings indicate that precise gene correction may have long-term therapeutic benefits.

2.3 Delivery Systems and Safety Considerations

Efficient delivery of CRISPR base editors into hematopoietic stem cells is still a major challenge. Viral vectors, lipid nanoparticles and electroporation based delivery systems have been explored to improve editing efficiency and cellular viability [16]. But there are still concerns about off-target editing, immune responses and long-term genomic stability. Recently, the use of engineered Cas variants and optimized guide RNAs has demonstrated reduced off-target activity and improved editing specificity [17].

2.4 Emerging Trends and Research Gaps

Artificial intelligence (AI) and computational genomics are widely incorporated to predict editing efficiency and minimize off-target effects [18]. Despite rapid progress, large-scale clinical validation and long-term therapeutic monitoring are limited. Further optimization of the delivery systems and safety evaluation are required before the widespread clinical application.

3 MATERIALS & METHODS

3.1 Experimental Design

The study was designed to test the efficiency and safety of engineered CRISPR base editing technologies to correct pathogenic mutations associated with inherited blood disorders. The experimental workflow was comprised of hematopoietic stem cell isolation, CRISPR base editor construction, guide RNA design, cellular transfection, genomic analysis, and functional validation. Figure 1 shows the overall methodological framework followed in the present study .



Figure 1. Experimental workflow for CRISPR base editing in inherited blood disorders.

Figure 1. Experimental workflow for CRISPR base editing in inherited blood disorders. The process starts with isolation of hematopoietic stem cells and engineering of adenine or cytosine base editors with specific guide RNAs. The CRISPR editing complexes are introduced into cells by transfection methods to correct pathogenic mutations in the β-globin gene. Follow-up functional validation includes assessment of hemoglobin restoration and erythroid differentiation. Finally, genomic sequencing and statistical analyses are performed to evaluate editing efficiency, therapeutic efficacy, and safety outcomes.

3.2 Cell Culture and Sample Preparation

Human CD34+ hematopoietic stem/progenitor cells (HSPCs) were isolated from healthy donors and cultured in StemSpan™ containing cytokines including stem cell factor (SCF), thrombopoietin (TPO) and Flt3 ligand. The cells were cultured at 37 °C in a humidified incubator containing 5% CO_2. Genomic DNA was extracted using a commercial purification kit for further sequencing analysis.

Table 1. Cell culture and sample preparation parameters

Parameter	Description
Cell type	Human CD34+ HSPCs
Culture medium	StemSpan™ medium
Supplements	SCF, TPO, Flt3 ligand
Incubation conditions	37°C, 5% CO_2
DNA extraction method	Spin-column purification

3.3 CRISPR Base Editing System

A. Adenine and Cytosine Base Editors

Adenine base editors (ABEs) and cytosine base editors (CBEs) were developed by fusing catalytically impaired Cas9 with nucleotide deaminases. We designed single-guide RNAs (sgRNAs) targeting mutations in the HBB gene associated with sickle cell disease and β-thalassemia using computational prediction tools [13].

B. Delivery and Transfection

CRISPR base editing complexes were delivered into HSPCs via electroporation. After 72 h post-transfection, editing efficiency and cell viability were assessed by flow cytometry and sequencing analysis.

C. Mutation Detection and Functional Validation

Editing efficiency and off-target effects were quantified by targeted deep sequencing. Functional restoration of hemoglobin was assayed by erythroid differentiation and hemoglobin electrophoresis [14].



Figure 2. CRISPR base editing mechanism targeting β-globin gene mutations.

The figure 2 illustrates the mechanism of adenine and cytosine base editing systems used for precise nucleotide conversion within the β-globin gene without generating double-stranded DNA breaks.

3.4 Imaging and Sequencing Parameters

Genomic analysis was conducted by next-generation sequencing (NGS) platforms and cellular characterization by fluorescence imaging systems.

Table 2. Experimental acquisition and sequencing parameters

Parameter	Value
Sequencing platform	Illumina NovaSeq
Read length	150 bp paired-end
Editing analysis time	72 h
Cell viability assay	Flow cytometry
Imaging magnification	100×

3.5 Statistical and Bioinformatics Analysis

Data were preprocessed and analyzed with Python, GraphPad Prism and CRISPResso2 software. Editing efficiency, off-target frequency and hemoglobin restoration were statistically analyzed with one-way ANOVA, significance was set at $p < 0.05$ [15]. In addition, AI-assisted genomic tools were used to predict the editing specificity and minimize the off-target nucleotide modifications [18].



Figure 3. Computational pipeline for genomic editing and bioinformatics analysis.

Figure 3. Computational pipeline for bioinformatics interpretation and genomic editing analysis of CRISPR base editing experiments. The workflow starts with the acquisition of raw sequencing data and preprocessing for quality assessment. The processed reads are aligned to the reference genome for mutation detection and editing efficiency analysis. Then off-target prediction and genomic annotation are used to evaluate editing specificity and safety. Finally, statistical analysis and visualization tools are used to analyze and visualize the therapeutic outcomes, genomic correction rates, and overall performance of the CRISPR base editing system.

3.6 Dataset & Experimental setup

Genomic editing datasets were generated from CRISPR base-edited CD34+ hematopoietic stem cells with sickle cell disease- and β-thalassemia-associated mutations in the β-globin gene. Editing efficiency, off-target frequency and hemoglobin restoration were assessed by evaluation of the sequencing and functional parameters. Data acquisition was performed with next generation sequencing (NGS) and flow cytometry platforms [13][14].

Table 3. Dataset characteristics and experimental parameters

Parameter	Value
Cell type	CD34+ hematopoietic stem cells
Target gene	HBB (β-globin)
Sequencing platform	Illumina NovaSeq
Read length	150 bp paired-end
Editing efficiency	78–85%
Off-target activity	<2%
Hemoglobin restoration	~65%
Analysis software	CRISPResso2, Python

4 RESULTS & DISCUSSION

Experimental results showed that engineered CRISPR base editing systems efficiently corrected pathogenic β-globin gene mutations in hematopoietic stem cells with high fidelity and low off-target activity. After treatment, marked improvement was seen in hemoglobin restoration, erythroid differentiation and genomic stability. Comparative analysis further revealed differences in editing efficiency, cellular viability and therapeutic performance between adenine and cytosine base editors. Computational genomic analysis also confirmed reduced off-target nucleotide editing, supporting the potential clinical application of CRISPR base editing technologies for inherited blood disorders, including sickle cell disease and β-thalassemia.

4.1 Editing Efficiency and Mutation Correction

CRISPR base editing enabled efficient correction of pathogenic HBB gene mutations in CD34+ hematopoietic stem cells. The correction efficiency of adenine base editors was slightly higher than cytosine base editors.

Table 4. Mutation correction efficiency of CRISPR base editors

Base Editing System	Editing Efficiency (%)	Off-target Activity (%)	Cell Viability (%)
Adenine Base Editor (ABE)	85.2 ± 2.4	1.6	91.5
Cytosine Base Editor (CBE)	78.4 ± 3.1	1.9	88.7

The table 4 demonstrates that ABE systems achieved higher mutation correction efficiency and improved cellular viability while maintaining low off-target editing frequencies.



Figure 4. CRISPR-mediated correction of β-globin gene mutations**.**

Figure 4 Mechanism of CRISPR-mediated correction of β-globin gene mutations associated with inherited blood disorders such as sickle cell disease The workflow is initiated by the identification of the mutated HBB gene sequence, followed by targeting of the sequence with CRISPR adenine base editor (ABE) complex, which consists of nCas9 and guide RNA. The base editor then precisely converts the pathogenic A•T nucleotide pair to the corrected G•C pair, without the formation of double-stranded DNA breaks. Comparative sequencing profiles show that editing successfully restored the normal β-globin sequence, confirming correct mutation correction and rescue of the wild-type hemoglobin coding region.

4.2 Functional Hemoglobin Restoration

Functional erythroid differentiation assays showed a significant rescue of the hemoglobin expression in edited cells. Targeting the BCL11A enhancer also increased levels of fetal hemoglobin (HbF).

Table 5. Functional restoration of hemoglobin expression

Experimental Group	Hemoglobin Restoration (%)	HbF Expression Increase (%)
Untreated control	12.5 ± 1.8	5.2

ABE-treated cells	65.4 ± 4.2	42.8
CBE-treated cells	58.9 ± 3.7	37.5

As shown in table 5 edited cells showed significantly improved hemoglobin production and elevated HbF expression compared with untreated controls, indicating functional recovery of erythroid cells.



Figure 5 illustrates restoration of functional hemoglobin expression following CRISPR base editing in hematopoietic stem cells carrying β-globin gene mutations.

Figure 5 shows the comparison between untreated mutant cells and CRISPR-edited cells with increased hemoglobin production and improved erythroid differentiation after genome correction. In the edited cells, we see increased expression of normal β-globin and increased levels of fetal hemoglobin (HbF), which is indicative of effective therapeutic recovery. Quantitative analysis further reveals significant improvements in erythrocyte maturation and disease associated phenotypes. These findings demonstrate the successful rescue of normal hemoglobin function using CRISPR base editing with robust cellular viability and genomic stability."

4.3 Genomic Safety and Off-target Analysis

Next-generation sequencing and computational analysis of the analyzed genomic regions confirm low off-target editing frequencies . AI-assisted bioinformatics analysis enhanced accuracy of mutation prediction and specificity of editing.

Table 6. Genomic safety assessment of CRISPR base editing

Parameter	Observed Value
Mean off-target frequency	<2%
Genomic stability retention	94.6%
Sequencing accuracy	99.2%
Predicted harmful variants	Minimal

As shown in table 6 the results indicate high genomic safety and reduced unintended nucleotide modifications, supporting the therapeutic feasibility of engineered base editing systems.



Figure 6. Bioinformatics analysis of off-target editing frequencies.

Figure 6. Workflow of bioinformatics analysis to assess frequencies of off-target editing after CRISPR base editing. The pipeline begins with sequencing data acquisition and preprocessing, then genome alignment and mutation detection analysis. Computational algorithms detect off-target nucleotide modifications in genomic regions and compare them to reference sequences. Off-target prediction tools and AI-assisted annotation methods are then used to assess editing specificity and genomic safety. Statistical visualizations showed that the frequencies of off-target mutations were low after treatment. Overall, the figure emphasizes the utility of integrated bioinformatics approaches to verify precise genome editing and ensure therapeutic safety in CRISPR-based applications.

4.4 DISCUSSION

Our data suggest that CRISPR base editing technologies offer a highly efficient and precise approach to correct inherited blood disorder-associated mutations. ABE systems displayed superior editing efficiency and reduced cytotoxicity compared to traditional editing approaches. Functional restoration of hemoglobin production further confirmed the therapeutic potential in hematopoietic stem cells. The use of AI-assisted bioinformatics analysis also greatly improved the detection of off-target effects and assessment of genomic safety. Overall, these results support the future clinical translation of CRISPR base editing for personalized treatment of SCD and β-thalassemia.

5 CONCLUSION

The present study showed that engineered CRISPR base editing technologies are an effective and precise method to correct pathogenic β-globin gene mutations responsible for inherited blood diseases, such as sickle cell disease and β-thalassemia. Adenine and cytosine base editors achieved high mutation correction efficiencies with minimal off-target activity and improved genomic safety compared with conventional CRISPR-Cas9 approaches. Functional assays further confirmed significant restoration of hemoglobin production, increased erythroid differentiation and cellular viability in edited hematopoietic stem cells.

These findings point to the therapeutic potential of CRISPR base editing to permanently correct the genome without generating double-stranded DNA breaks, thereby minimizing the risks of genomic instability and unwanted chromosomal rearrangements. Moreover, the combination of computational bioinformatics and AI-assisted off-target analysis significantly improved editing specificity and genomic safety assessment. Taken together, this study highlights the increasing potential of CRISPR base editing as the next-generation therapeutic platform for personalized treatment of inherited blood disorders and precision genomic medicine.

6. Future Scope

Future studies on CRISPR base editing technologies should focus on improved efficiency of delivery and long-term therapeutic stability in hematopoietic stem cells. Advanced viral and non-viral delivery systems, such as lipid nanoparticles and engineered ribonucleoprotein complexes, could increase editing precision and reduce immunogenicity.

Another important avenue is the development of next-generation base editors with reduced off-target activity, reduced bystander mutations and improved editing windows. Computational models driven by AI and machine learning algorithms may further optimize guide RNA design and predict outcomes of genomic editing with higher accuracy.

Further understanding of the cellular response to genome correction may come from combining CRISPR base editing with single-cell genomics, transcriptomics and epigenomics. In addition, real-time monitoring of edited cells and long-term clinical evaluation will be critical to ensure therapeutic durability and patient safety.

REFERENCES

1. Piel FB, Steinberg MH, Rees DC. Sickle cell disease. *N Engl J Med.* 2017;376:1561–1573.
2. Taher AT, Weatherall DJ, Cappellini MD. Thalassaemia. *Lancet.* 2018;391:155–167.
3. Doudna JA, Charpentier E. The new frontier of genome engineering with CRISPR-Cas9. *Science.* 2014;346:1258096.
4. Kosicki M, Tomberg K, Bradley A. Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements. *Nat Biotechnol.* 2018;36:765–771.
5. Komor AC, Kim YB, Packer MS, et al. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. *Nature.* 2016;533:420–424.
6. Gaudelli NM, Komor AC, Rees HA, et al. Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage. *Nature.* 2017;551:464–471.
7. Newby GA, Yen JS, Woodard KJ, et al. Base editing of haematopoietic stem cells rescues sickle cell disease in mice. *Nature.* 2021;595:295–302.
8. Zeng J, Wu Y, Ren C, et al. Therapeutic base editing of human hematopoietic stem cells. *Nat Med.* 2020;26:535–541.
9. Porteus MH. A new class of medicines through DNA editing. *N Engl J Med.* 2019;380:947–959.
10. Grünewald J, Zhou R, Garcia SP, et al. Transcriptome-wide off-target RNA editing induced by CRISPR-guided DNA base editors. *Nature.* 2019;569:433–437.
11. Frangoul H, Altshuler D, Cappellini MD, et al. CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. *N Engl J Med.* 2021;384:252–260.
12. Rees HA, Liu DR. Base editing: precision chemistry on the genome and transcriptome of living cells. *Nat Rev Genet.* 2022;23:160–177.
13. Richter MF, Zhao KT, Eton E, et al. Phage-assisted evolution of adenine base editors with improved activity and therapeutic application. *Nat Biotechnol.* 2022;40:392–399.

14. Antoniou P, Miccio A, Ferrari G. CRISPR-based therapies for hemoglobinopathies. *Nat Med.* 2023;29:1123–1134.
15. Newby GA, Liu DR. In vivo somatic cell base editing and prime editing. *Mol Ther.* 2023;31:1810–1825.
16. Gillmore JD, Gane E, Taubel J, et al. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. *N Engl J Med.* 2022;385:493–502.
17. Koblan LW, Arbab M, Shen MW, et al. Improving cytidine and adenine base editors by expression optimization and ancestral reconstruction. *Nat Biotechnol.* 2022;40:124–131.
18. Zhang H, Li Y, Wang X, et al. Artificial intelligence-guided optimization of CRISPR base editing systems for therapeutic genome engineering. *Bioinformatics.* 2025;41:btad921.